A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 90, Issue 8, 1996, Pages 497-499

  Matera, M G ^a   Caputi, M ^a   Cazzola, M ^b,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; SALMETEROL;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VAGUS TONE;

EID: 0029823876     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90178-X     Document Type: Article

References (14)

1. Humphreys DM. Is cholinergic tone pathological in chronic airflow obstruction? Res Clin Forums 1991; 13: 7-13.
2. Barnes PJ. Bronchodilators: basic pharmacology. In: Calverley PMA, Pride NB, eds. Chronic Obstructive Pulmonary Disease. London: Chapman and Hall, 1995, pp. 391-417.
3. Chapman KR. Clinical implications of anticholinergic bronchodilator therapy in COPD. Res Clin Forums 1991; 13: 43-50.
4. Cazzola M, Santangelo G, Piccolo A et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103-107.
5. Matera MG, Cazzola M, Vinciguerra A et al. A comparison of the bronchodilating effects of salmeterol, salbutamol, and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol (in press).
6. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
7. Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev 1992; 72: 699-729.
8. 2-adrenoceptors. J Appl Physiol 1988; 65: 700-705.
9. Bai TR, Lam R, Prasad FYF. Effects of adrenergic agonists and adenosine on cholinergic neurotransmission in human tracheal smooth muscle. Pulm Pharmacol 1989; 1: 193-199.
10. Baker DG, Herbert DA, Mitchell RA. Cholinergic neurotransmission in airway ganglia: inhibition by norepinephrine. Physiologist 1982; 25: 225.
11. 2-adrenoceptor stimulant, on neuroeffector transmission in human bronchial tissue. Respiration 1991; 58: 163-166.
12. Jeppsson AB, Kallstrom BL, Waldeck B. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol Toxicol 1992; 71: 272-277.
13. Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 62-66.
14. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.